Personalised neoantigen vaccine + PD-1 blockade
The vaccine teaches the immune system what to hunt; PD-1 blockade stops the tumour from switching the hunters off.
Intismeran + pembrolizumab: 49% reduction in recurrence in phase 2b, and phase 3 INTerpath-001 positive (August 2026). Autogene cevumeran + atezolizumab in pancreatic cancer.
Pages like this
not linked directly; found by shared links- IdeaPersonalised cancer vaccines at commodity cost through fully automated manufacturing
Shares Autogene cevumeran, Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Melanoma.
- Key paperKEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery
Shares INTerpath-001 (V940-001), Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Pembrolizumab.
- IdeaPersonalised vaccines given only when the blood test turns positive
Shares Autogene cevumeran, Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Melanoma.
- IdeaWhat makes a neoantigen actually immunogenic?
Shares Autogene cevumeran, Intismeran autogene, Personalised neoantigen (mRNA) vaccines.
- InstitutionUniversity Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz
Shares Autogene cevumeran, Personalised neoantigen (mRNA) vaccines, Melanoma, Pancreatic ductal adenocarcinoma.
- CompanyBioNTech
Shares Autogene cevumeran, Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer, Personalised neoantigen (mRNA) vaccines, Pancreatic ductal adenocarcinoma.
- PairingPD-1 failure → TIL therapy
Shares Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- TrialKEYNOTE-006
Shares Pembrolizumab, Melanoma, Immune checkpoint inhibitors.